[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cutaneous-melanoma-stage-iv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cutaneous-melanoma-stage-iv":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100604340","symptoms-of-immune-checkpoint-inhibitor-therapy-in-cutaneous-melanoma-100604340",false,"NCT07148245","Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma","Characterization of the Symptom Experience of Patients With Cutaneous Melanoma Receiving Immune Checkpoint Inhibitor Therapy","Inclusion Criteria:\n\n* Adults ≥18 years of age\n* Able to speak and read English\n* Diagnosed with stage IIB, III, or IV cutaneous melanoma\n* Participants who are scheduled to receive \\>=1 immune checkpoint inhibitor at University of California San Francisco medical center locations. Participants on targeted therapies (e.g., BRAF or mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors) will be eligible.\n* Provide written informed consent to participate in this study.\n* Participants with stage IIB or higher cutaneous melanoma\n\nExclusion Criteria:\n\n* Participants will be excluded if they are unable to complete study requirements.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer. With this rapid shift in treatment, significant gaps in knowledge exist regarding the impact of ICIs on patients' symptom experiences. An in-depth characterization of inter-individual differences in patients' symptom experiences will fill this knowledge gap and assist with the early detection of ICI toxicity; guide symptom management; inform treatment decision making; and refine ICI-symptom instrument development. Furthermore, given the limited knowledge in this area, the identification of demographic, clinical, environmental, and molecular risk factors associated with a worse symptom experience is warranted. This is a longitudinal, prospective study evaluating the symptoms that immune checkpoint inhibitors may cause in patients with cutaneous melanoma.",[24,25,26,27],"Cutaneous Melanoma","Cutaneous Melanoma, Stage III","Cutaneous Melanoma by AJCC V7 Stage","Cutaneous Melanoma, Stage IV",[29],"Toxicity","RECRUITING","2025-11-05",{"date":33,"type":34},"2025-11-10","ACTUAL",{"date":36,"type":34},"2025-10-13",{"date":38,"type":20},"2027-06-30",{"name":40,"class":41},"University of California, San Francisco","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":71,"locationsCount":4},"100428020","ifx-hu20-expanded-access-program-100428020","NCT04853602","IFx-Hu2.0 Expanded Access Program","Inclusion Criteria:\n\n* To request more information use Responsible Party contact information provided in this record\n\nExclusion Criteria:\n\n* To request more information use Responsible Party contact information provided in this record","EXPANDED_ACCESS","Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC) who have failed all available treatment options.\n\nTo request access, use Responsible Party contact information provided in this record..",[25,27,52,53],"Merkel Cell Carcinoma","Cutaneous Squamous Cell Carcinoma",[55,56,57,58,59,60,61,62,63,64,65,66],"CM","MCC","cSCC","pDNA","plasmid DNA","pAc\u002Femm55","IFx-Hu.20","Immunotherapy","Gene Therapy","Immunology","Oncology","Immuno-Oncology","AVAILABLE","2024-08-08",{"date":70,"type":34},"2024-08-12",{"name":72,"class":73},"TuHURA Biosciences, Inc.","INDUSTRY"]